ଓଭାରିଆନ୍ କ୍ୟାନ୍ସର
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Who can joinମହିଳା
ବୟସ 18+ ବର୍ଷ
ଅଧ୍ୟୟନର ପ୍ରକାରଫେଜ୍ 3: ସାଧାରଣ ଚିକିତ୍ସା ସହିତ ତୁଳନା
What it testsଗୋଟେ medicine
କିଏ ଯୋଗ ଦେଇପାରିବେ ଆଉ କିଏ ପାରିବେ ନାହିଁ, ତାହାର ପୂରା ତାଲିକା ରେଜିଷ୍ଟ୍ରିରେ ଅଛି। ଟ୍ରାଏଲ୍ ଟିମ୍କୁ ପଚାରନ୍ତୁ, କିମ୍ବା ଆମକୁ ଲେଖନ୍ତୁ ଆଉ ଆମେ ଏହାକୁ ସହଜ ଭାଷାରେ ବୁଝେଇଦେବୁ।
କେଉଁଠିକୁ ଯିବେ
ଏହି ଟ୍ରାଏଲ୍ ପାଇଁ ଭାରତରେ 9 ଟି ହସ୍ପିଟାଲ୍ ରୋଗୀ ନେଉଛନ୍ତି।
Gujarat Cancer & Research InstituteAhmedabadDirection ↗
Saroj Gupta Cancer Center and Research Institute SGCC&RIକୋଲକାତାଦିଗ ↗
Tata Memorial HospitalMumbaiDirection ↗
National Cancer Institute Nagpurନାଗପୁରଦିଗ ↗
HCG Manavata Cancer Centreନାସିକଡିରେକ୍ସନ୍ସ ↗
Ruby Hall Clinicପୁଣେଦିଗ ↗
HCG Cancer Centre VadodaraVadodaraDirections ↗
Mahamana Pandit Madan Mohan Malaviya Cancer Centreବାରଣାସୀଦିଗ ↗
King George Hospitalବିଶାଖାପାଟଣାଦିଗ ↗
ରେଜିଷ୍ଟ୍ରି ସାରାଂଶ (ଟେକ୍ନିକାଲ୍)
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.
Sponsor: Daiichi Sankyo
NCT06819007 on ClinicalTrials.gov
Last updated on the registry 2 Jul 2026 · read by us 20 Oct 2026